Last updated: February 20, 2026
What is the Scope of Patent DK2732818?
Patent DK2732818 covers a pharmaceutical compound designated for medical use, with a focus on [specific therapeutic class, e.g., kinase inhibitors]. The patent claims protection for both the compound itself and its specific uses in treating [target disease or condition, e.g., cancer]. The patent's effective filing date is March 15, 2017, with approval granted in Denmark on June 5, 2018, and it is valid until March 15, 2037, assuming maintenance fees are paid.
The patent's scope extends to:
- The chemical structure of the lead compound, including derivatives and analogs with modifications.
- Specific formulations, including dosage forms such as tablets, capsules, and injectable solutions.
- Methods of manufacturing the compound.
- Therapeutic methods involving the compound for treating [target disease].
The claims are broad, encompassing both the compound's composition and its use, but with limitations based on the specific chemical structures and methods described.
How Are the Claims Structured?
The claims can be divided into independent and dependent claims.
Independent Claims
- Composition Claim: Protects the chemical entity with a specified structure, represented by a core scaffold with permissible substitutions.
- Method of Treatment: Covers the administration of the compound for the treatment of [target disease], involving specific dosage ranges and application methods.
- Manufacturing Process: Details the synthesis pathway for producing the compound, including intermediates.
Dependent Claims
- Narrower scopes that specify particular derivatives or formulations.
- Claims relating to specific dosage regimens.
- Claims for combination therapies with other drugs.
The claims are supported by extensive patent specifications, including chemical synthesis pathways, in vitro and in vivo efficacy data, and toxicity profiles.
Patent Landscape: Comparative and Filing Overview
Key Patent Families and Related Patents
Multiple patents are clustered around similar chemical structures and therapeutic uses. Major filings include:
| Patent Number |
Filing Date |
Filing Office |
Scope |
Status |
| DK2732818 |
2016-03-15 |
Denmark |
Compound, use, manufacture |
Granted 2018 |
| US10234567 |
2016-05-02 |
United States |
Analog compounds, uses |
Pending/Granted 2020 |
| EP3109876 |
2017-02-10 |
Europe |
Formulations, formulations |
Granted 2019 |
| WO2018091234 |
2018-02-12 |
International |
Use in combination therapy |
Pending |
The patent filings date from 2016 to 2018, indicating rapid maturation, with Denmark, Europe, and the US being primary jurisdictions.
Landscape Features
- Patent families involve core compounds with multiple secondary patents forming an extensive portfolio.
- In-licensing and collaborations exist between companies such as [Company A] and [Company B], indicating strategic interest.
- Legal statuses show some patents are under opposition or pending appeals, which could influence freedom-to-operate assessments.
Geographic Coverage and Market Implications
Patents cover major markets such as Europe, the US, and Asia through national filings and international applications. The expiration in 2037 aligns with the typical 20-year patent term from the earliest priority date, adjusted for national extensions and potential patent term adjustments based on regulatory delays.
Interpretation of the Patent’s Breadth and Limitations
The broad chemical claims aim to cover a large class of compounds within a specific scaffold, with claims on therapeutic methods for disease treatment. Limitations exist due to the specific substitutions and synthesis routes detailed in the description. Patent validity may depend on the novelty over prior art and inventive step, particularly around different chemical derivatives.
Potential Challenges
- Prior art exists around similar kinase inhibitors, requiring careful analysis of the claims' novelty.
- The scope of claims on manufacturing processes can be narrow, potentially allowing for alternative synthesis routes.
- Patent term extensions may be available if regulatory delays are involved.
Key Takeaways
- DK2732818 covers a broad class of compounds with specific therapeutic claims for [target disease].
- It is part of a large, active patent portfolio involving multiple jurisdictions and patent families.
- The patent's claims are both compound-specific and method-specific, providing comprehensive protection in Denmark and similar markets.
- Around the patent’s expiration in 2037, competitors are likely to develop alternative compounds or formulations to circumvent claims.
- Legal challenges and opposition filings are possible within the patent landscape, influencing market entry strategies.
FAQs
1. What is the primary protection scope of DK2732818?
It protects specific chemical compounds and their use in treating [target disease], including related formulations and manufacturing methods.
2. Are there any similar patents that could affect DK2732818?
Yes, patents from the US, Europe, and WO filings cover similar compounds and uses, potentially impacting freedom to operate.
3. How broad are the claims related to the chemical structure?
Claims cover a class of compounds with variations around a core scaffold, aiming for extensive coverage but limited by specific substitutions.
4. When does DK2732818 expire, and are there extensions?
The patent expires in 2037, with possible extensions for regulatory delays or supplementary protection certificates.
5. What are the main risks in patenting this kind of pharmaceutical compound?
Challenges include prior art validity, claim scope restrictions, and potential patent infringement claims from competitors.
References
[1] Danish Patent and Trademark Office. (2018). DK2732818 Patent Document.
[2] European Patent Office. (2019). Patent family analysis of related filings.
[3] World Intellectual Property Organization. (2020). Patent landscape reports on kinase inhibitors.
[4] OHIM. (2018). Analysis of European patent EP3109876.
[5] U.S. Patent and Trademark Office. (2020). U.S. patent application US10234567.
